Abstract: The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds of the present invention can be used as antimicrobials, and bleaching agents. The compounds of the present invention are also suitable for use as coupling agents.

Abstract: The present invention is directed to a method of treating a lack of normal breathing control including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions. In an aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a combination of two or more compounds, at least one of which treats lack of normal breathing. In one aspect, a compound is an S-nitrosylating agent.

Abstract: The presently disclosed and claimed invention is directed to anti-microbial orthodontic apparatus and anti-microbial orthodontic compositions comprising an effective amount of a selenium compound, kits containing same, and methods of producing and using said anti-microbial orthodontic apparatus and anti-microbial orthodontic compositions.

Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

Abstract: The present invention relates to compounds and methods for the treatment of cardiovascular diseases and disorders. Compounds according to the present invention may comprise an optionally substituted phenyl ring linked to an aromatic or alkyl group by a spacer, wherein the spacer comprises two groups selected from selenium, sulfur, S(O) and S(O)2 and may further optionally comprise an alkylene, alkenylene, cycloalkylene or arylene moiety between the respective selenium, sulfur, S(O) and S(O)2 groups.

Abstract: The invention concerns the use of at least a molecule containing selenium, in an amount corresponding to a daily dose of about 2 to 40 mg, even 80 mg of atomic selenium equivalent, on its own or combined with other synergetic molecules for controlling oxidative stress and excessive inflammatory reaction: zinc, vitamin E, vitamin C, iron binder, glutathione precursor, copper and/or copper input binder, for preparing a medicine for treating severe systemic inflammatory response syndrome, in particular any acute infectious condition endangering the patient's life whether of bacterial, parasitic, fungal or viral origin, and any condition corresponding to a severe onset of inflammatory pathology bringing about an exacerbation of cytokine secretion. The invention is applicable in human and veterinary medicine.

Abstract: The invention relates to a method of treatment for muscular dystrophies, including Duchenne, Becker, limb-girdle, facioscapulohumeral, congenital muscular dystrophies and the like using a combination of nitric oxide-releasing and anti-inflammatory compounds.

Abstract: Specific plant extracts are applied topically to upregulate genes which code for proteins to prevent the build-up of and mitigate the activity of various harmful materials within the skin. These upregulated proteins include glutathione transferases, peroxiredoxins, oxidoreductases, glutaredoxins and glutathione syntheses. These proteins produce additional glutathione, glyoxalase I, maintain cellular redox homeostasis, reduce hydrogen peroxide and alkylhydroperoxides, and conjugate glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Keratinocytes have been induced to significantly upregulate glutathione and glyoxalase I protein expression. Additionally, keratinocytes pre-treated with diallyl trisulfide have increased viability when exposed to ozone, UV radiation or cigarette smoke extract.

Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

Abstract: A novel neuroprotective agent is disclosed for the treatment and prevention of neurodegenerative disorders which is based on the administration of an effective amount of a tellurium compound which has a specific ability to induce the differentiation and interfere with apoptotic cell death pathways of neuronal PC-12 cells.

Abstract: This invention pertains to the discovery of a novel family of thiolesters and uses thereof. Also provided for are viricidal compounds and pharmaceutical formulations comprising these novel thiolesters. The invention also provides thiolester-inactivated viruses and thiolester-complexed viral proteins.

Abstract: The invention provides extracts and preparations based on the species Tulbaghia violacea (Harv.) (wild garlic), which elicits a significant antimicrobial, preferably antifungal activity in vitro and in vivo, even under field and glasshouse conditions. Moreover, these extracts deriving from the soil parts as well as of the aerial parts of the plant elicit a significant bio-stimulatory activity, expressed, above all, by an increased growth metabolism supporting seed growth. Furthermore, combined extracts or preparations from Tulbaghia violacea and species of the genus Agapanthus show a higher antifungal and bio-stimulatory efficacy as compared to the extracts or preparations of the single species, indicating that synergism is participated in the involved biological processes.

Abstract: This invention provides novel HIV-interacting host factors. The invention also provides methods of using the HIV-interacting host factors to screen for compounds that inhibit HIV infection. The methods comprise first screening test compounds for modulators of an HIV interacting host factor disclosed herein, and then further screening the identified modulating compounds for ability to inhibit HIV infection. The invention further provides methods and pharmaceutical compositions for treating diseases and conditions associated with HIV infection.

Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.

Abstract: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.

Abstract: The invention describes novel compositions comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The invention also provides novel kits comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor compound, and, optionally, at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating gastrointestinal disorders; (h) treating inflammatory disorders; and (j) treating respiratory disorders. The apocynin compound may preferably be apocynin. The nitric oxide donor compound may preferably be isosorbide dinitrate and/or isosorbide mononitrate.

Abstract: The formulation provides a method of treating headaches, neck, joint and inflammatory-type pain in a mammalian subject by administering to the subject a therapeutically effective amount of a nitrate-containing compound and a therapeutically effective amount of a selenium-containing compound. The formulation also provides kits and systems for practicing the subject methods.

Abstract: The present invention relates to compositions containing signal transduction modulator compounds, to methods for treating or preventing inflammation, or promoting healthy joints, using the compounds and to kits for the same.

Abstract: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o Heliobacter pylori infections, colorectal cancer, Zolliger-Ellison syndrome, Familial British Dementia and Familial Danish Dementia.

Abstract: The invention provides methods and compositions relating to Kuz involvement in angiogenesis.

Abstract: The present invention discloses a method for reducing alopecia and bladder toxicity associated with the anti-cancer agent cyclophosphamide. The method comprises administering to an individual, in need of such a treatment, cyclophosphamide and a selenium compound. The selenium compounds may be administered before, during or after administration of the anti-cancer agent.

Abstract: Compositions are provided for the topical treatment of cancer consisting of lotions, creams, sprays, suppositories or slow-release transdermal patches containing lipid-soluble, skin-penetrating organic selenium compounds in combination with inert carriers in therapeutically effective amounts of selenium compound. The selenium compounds are medium linear chain dialkyl diselenides and precursors such as alkyl selenols. Preferred compositions employ R—Se—Se—R compounds where R is from 6 to 8 carbon atoms, and most specifically di-n-hexyl diselenide. Commonly used carriers may be purified hydrocarbon fractions, oils, with or without added fat-soluble vitamins, water and emulsifying agents.

Abstract: A skin dressing is adapted, on activation, to release one or more S-nitrosothiols, preferably S-nitroso-L-glutathione. S-nitrosothiols decompose spontaneously to produce nitric oxide, which has beneficial effects on tissues, particularly in wound healing.

Abstract: The present invention provites a compound having the following structure: wherein, in the formula: X is selected from the group consisting of hydroxy, substituted hydroxy, halogen, thiol, and substituted thiol; one of Y1 and Y2 is hydrogen or alkyl, and the other is Z-W, wherein Z is a single bond, or a divalent group having alkane or substituted alkane having two hydrogen atoms removed, and W is hydroxy, substituted hydroxy, aldehyde, carboxyl, or substituted carboxyl; and R1-R24 are independently selected from the group of hydrogen, alkyl, and substituted alkyl.

Abstract: Chemical formulations and methods for reducing muscle and joint soreness are disclosed. A representative chemical formulation includes compounds such as a selenium-compound, chondroitin sulfate, glucosamine, and/or methylsulfonylmethane. A representative method for reducing muscle and joint soreness includes administering the chemical formulation to a host.

Abstract: 3,5-di-substituted-4-hydroxybenzylidene phosphonates and sulfonates useful in treating inflammatory disease, particularly osteoarthritis, and elastomeric particles for oral delivery of drugs are disclosed.

Abstract: The invention relates to the food and medical industries, medical cosmetics, dermatology, agriculture and the mixed feed industry. According to the invention vicinal dithioglycole (common formula RCH(SH)CH(SH)R?1 (I)) is used as a food additive, a food product, physiologically-active substances and active ingredients of forage additives and of forage, in cosmetic and/or dermatological and skin-therapeutic remedies. The invention comprises methods for producing such additives, products and remedies. The substance of formula (I) stimulates physiological processes, increases human and animal immunity, inhibits undesirable process in organisms and food products, produces curative and preventive action of skin, hair and nails and after vicinal dithioglycole is administered the intoxication effect of alcohol consumption known as hang-over is completely remored.

Abstract: The present invention is directed to pest-controlling compositions comprising as active ingredients one or more ?-diones, particularly ?-diketones and ?-triketones, and to the use of these compositions inter alia for preventing, eradicating, destroying, repelling or mitigating harmful, annoying or undesired pests including insects, arachnids, helminths, molluscs, protozoa and viruses. The present invention is further directed to processes of preparing ?-diones by de novo synthesis or from natural sources such as volatile oil-bearing plants from families including Alliaceae, Apiaceae, Asteraceae, Cannabinaceae, Lamiaceae, Pteridaceae, Myrtaceae, Myoporaceae, Proteaceae, Rutaceae and Zingiberaceae.

Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

Abstract: Disclosed herein are DNA molecules isolated from Streptococcus agalactiae and other bacterial species encoding a bifunctional enzyme with ?-glutamylcysteine synthetase and glutathione synthetase activities. Also disclosed are bifunctional enzymes with ?-glutamylcysteine synthetase and glutathione synthetase activities, uses of bifunctional enzymes with ?-glutamylcysteine synthetase and glutathione synthetase activities, uses of inhibitors of bifunctional enzymes with ?-glutamylcysteine synthetase and glutathione synthetase activities, and uses of DNA molecules encoding bifunctional enzymes encoding enzymes with ?-glutamylcysteine synthetase and glutathione synthetase activities.

Abstract: A biofilm-inhibiting medical product includes a carrier formed from a natural, bioremodelable material, whereby the carrier includes a biocidal bismuth thiol agent and/or one or more other biofilm-inhibiting or wound healing agents. A method for using the biofilm-inhibiting medical product to treat a wound or tissue defect in a patient's body is described.

Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.

Abstract: Compositions are provided for the topical treatment of cancer consisting of lotions, creams, sprays, suppositories or slow-release transdermal patches containing lipid-soluble, skin-penetrating organic selenium compounds in combination with inert carriers in therapeutically effective amounts of selenium compound. The selenium compounds are medium linear chain dialkyl diselenides and precursors such as alkyl selenols. Preferred compositions employ R—Se—Se—R compounds where R is from 6 to 8 carbon atoms, and most specifically di-n-hexyl diselenide. Commonly used carriers may be purified hydrocarbon fractions, oils, with or without added fat-soluble vitamins, water and emulsifying agents.

Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.

Abstract: The invention pertains to compositions and methods to treat the adverse effects of mustard chemicals and other toxic compounds, such as chemical warfare agents, exposure to which normally induces vesicating type response in mammals. In a rodent eye model at fixed concentrations of such a vesicant, compositions comprising a matrix metalloproteinase inhibitor, MMPI, a significant reduction in morbidity is achieved. with increased concentrations of the compositions of this invention, as compared with vehicle alone. Furthermore, compositions comprising the MMPI and in addition, an anti-inflammatory compound, in a vehicle appropriate to the type of tissue damage to be protected against from vesicant exposure, achieves both reduction in total tissue damage and inflammation, as compared with anti-inflammatory composition alone. Chemicals having more than one property, such as MMPI and AIA properties, are also disclosed.

Abstract: Compounds having anti-androgenic activities are disclosed. Further disclosed are methods of using the compounds to prevent or treat androgen-dependent diseases or to provide nutraceutical benefits. Pharmaceutical and nutraceutical compositions containing the anti-androgenic compounds are also disclosed.

Abstract: The purpose of this invention is: new selenohydroxy acid compounds and their derivatives; their process for the preparation; use of the new compounds as precursors of L(+)-selenomethionine and/or source of selenium in human or animal nutrition, in cosmetics and pharmaceutics; and nutritional, cosmetic and pharmaceutical compositions containing them.

Abstract: The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy or chemotherapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.

Abstract: Novel compositions and methods of treating and preventing a viral infection are provided. A method of blocking a viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which involves administering to a subject suffering or about to suffer from a viral infection a therapeutically effective amount of a substance having serine protease inhibitory activity or serpin activity. Among the substances found to be useful are ?1-antitrypsin (AAT), peptide derivatives from the carboxy terminal end of AAT and synthetic drugs mimicking the action of such substances. The invention is particularly well suited for checking a viral infection mediated by members of herpesviridae family.

Abstract: Disclosed are marine coating compositions that are useful to inhibit the fouling of a marine structure by a broad spectrum of organisms. Generally, the marine coating composition comprises an antifouling agent and an organic vehicle.

Abstract: The present disclosure describes a novel composition for the treatment and/or prevention of neurogenic inflammation. Such composition is also useful in the treatment and/or prevention of disease states and conditions associated with neurogenic inflammation. Such disease states and conditions include, but are not limited to, migraine headache, arthritis and fibromyalgia. The composition comprises nutrient compounds in a novel combination and formulation to treat and/or prevent neurogenic inflammation and disease states and conditions associated therewith. By reducing neurogenic inflammation, the compositions of the present disclosure reduce the symptoms associated with neurogenic inflammation, such as pain and systemic inflammation in general.

Abstract: Methal sulfonyl methane, glucosamine sulfate, folic acid and vitamin B-12 composition for the enhancement of the execution of transmethylation activity within every living cell in the body for humans and all other members of every other genus and species in the entire Animal Kingdom. Elemental Cellular Therapy is a genetic, cellular and disease-modifying therapy which enhances the systemic conduct of genetic and cellular transmethylation activity resulting in enhancement of concerted genetic and cellular metabolic, physiologic and homeostatic processes.

Abstract: The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, personal care, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed.

Abstract: A patient with dyslipidemia is treated with a cholesterol blood level lowering effective amount of a non-statin cholesterol lowering agent and an amount of nitric oxide (NO) donating compound effective to mediate increase in nitric oxide bioactivity in blood.

Abstract: Compositions and methods are disclosed wherein one or more steroid hormones are combined in a mixture with a sulfur-containing compound. The sulfur-containing compound increases the absorption of the steroid hormone through a mucosal surface, such as skin, oral mucosa, and mucosa of the gastrointestinal tract.

Abstract: An aqueous ophthalmic composition comprising a branched glycerol compound selected from the group consisting of a branched, glycerol monoalkyl ether, a branched, glycerol monoalkyl amine, a branched, glycerol monoalkyl sulfide, or any mixture thereof, present in a total amount of from 0.05 ppm to 1,000 ppm; a cationic antimicrobial component, and having an osmolality in a range from 200 mOsmol/kg to 400 mOsmol/kg. The presence of the branched glycerol compound enhances the biocidal efficacy of the aqueous ophthalmic composition containing one or more cationic antimicrobial components.

Abstract: The present invention relates to a preparation for stimulating or enhancing an immune system comprising one or more agents that stimulate T-lymphocytes in vivo. Such a preparation can be sued in the prophylaxis and/or treatment of a medical condition. The invention further relates to a preparation for use in a pharmaceutical or food product and to a preparation for medical use.

Abstract: The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium and which comprises a concentration of the metal(s) of at least 60 mg/ml. The solution further comprises at least one compound selected from the group comprising iodine, potassium iodide, sodium iodide, iron, iron chloride, zinc oxide, manganese sulphate, sodium selenite, copper carbonate, sodium carbonate, anhydrous disodium EDTA and sodium hydroxide. The trace element solution is prepared by a method consisting essentially of the steps of preparing a MnCO3 mixture in a container; adding an EDTA/NaOH mixture to the container and subsequently adding at least one metal compound; and adding Na2SeO3 to the container to obtain the trace element solution. The method also comprises the step of adding CrCl3.6H2O to the trace element solution.

Abstract: The field of the present invention comprises pharmaceuticals and pharmaceutical treatments, including, for example, (i) compounds and formulations which cause the augmentation of anti-cancer activity (i.e., by enhancement of the lethal cytotoxic action in stimulatory [inducing oxidative stress] and/or depletive [decreasing anti-oxidative capacity] manner) of chemotherapeutic agents, in a selective manner; (ii) methods of administering said anti-cancer augmentation compounds and formulations; (iii) delivery devices containing said anti-cancer augmentation compounds and formulations; and (iv) methods of using said anti-cancer augmentation compounds, formulations, and devices to treat subjects in need thereof.

Abstract: Injectable microfoam for scleroteraphy. The sclerotherapy of varices is based on the injection of liquid substances capable of suppressing them. The present invention relates to the preparation of sclerosing substances in the form of a microfoam. The microfoam is prepared with sclerosing agents, and is then injected in the vein to be treated, so that the microfoam displaces the blood contained in the vein and provides for the contact of the sclerosing agent with the vascular endothelium, with a predetermined known concentration and during a controllable time.